This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Muscarinic acetylcholine receptor M2 (CHRM2; HM2)	<p>An <i>in vitro</i> study determined the structure of HM2, which could be used to develop subtype-selective modulators of muscarinic receptors. Those receptors are potential targets in neurological diseases. A crystal structure of HM2 bound to an antagonist revealed an active site binding pocket that is conserved between subtypes and potential allosteric sites that are not conserved. Next steps could include designing ligands that bind in the allosteric sites and solving the structures of additional subtypes of muscarinic receptors.</p> <p>SciBX 5(7); doi:10.1038/scibx.2012.184 Published online Feb. 16, 2012</p>	Unpatented; licensing status not applicable	<p>Haga, K. <i>et al. Nature</i>; published online Jan. 25, 2012; doi:10.1038/nature10753 Contact: Takuya Kobayashi, Kyoto University Faculty of Medicine, Kyoto, Japan e-mail: t-coba@mfour.med.kyoto-u.ac.jp Contact: Tatsuya Haga, Gakushuin University, Tokyo, Japan e-mail: tatsuya.haga@gakushuin.ac.jp Contact: Brian K. Kobilka, Stanford University School of Medicine, Stanford, Calif. e-mail: kobilka@stanford.edu</p>